Mirai Bio Announces Strategic Collaboration with Thermo Fisher Scientific

Published: 2025-05-20 14:50:49 ET TMO

Published on 05/20/2025 at 14:50

Mirai Bio announced a strategic collaboration with Thermo Fisher Scientific to benefit the life sciences and genetic medicines marketplace. Under the terms of the collaboration, Thermo Fisher's developmental and current Good Manufacturing Practice (cGMP) services, commercial manufacturing capabilities and global capacity will be paired with Mirai's innovative technology platform for optimizing the design, delivery and development of novel nucleic acid therapeutics. Mirai was founded by Flagship Pioneering to provide industry partners with fully integrated end-to-end services.

Its proprietary machine intelligence-based platform enables the high-throughput design and in vivo testing of ideal tissue-targeted delivery vehicles and facilitates seamless, rapid industrialization of development candidates. Mirai's collaboration with Thermo Fisher is a new strategic engagement that will initially leverage the capabilities of Thermo Fisher's facility for RNA and Advanced Formulations. This collaboration includes a direct investment into Mirai as part of Flagship's existing partnership with Thermo Fisher that seeks to jointly develop transformative capabilities for the industry.